Institution
Tel Aviv Sourasky Medical Center
Healthcare•Tel Aviv, Israel•
About: Tel Aviv Sourasky Medical Center is a healthcare organization based out in Tel Aviv, Israel. It is known for research contribution in the topics: Population & Medicine. The organization has 6044 authors who have published 9658 publications receiving 353897 citations. The organization is also known as: Ichilov Hospital.
Topics: Population, Medicine, Cancer, Pregnancy, Retrospective cohort study
Papers published on a yearly basis
Papers
More filters
••
European Centre for Disease Prevention and Control1, Centers for Disease Control and Prevention2, Tel Aviv Sourasky Medical Center3, ALFA4, Tufts University5, Karolinska University Hospital6, University of Geneva7, University of California, Los Angeles8, Royal Brisbane and Women's Hospital9, Brown University10, Brigham and Women's Hospital11
TL;DR: A group of international experts came together through a joint initiative by the European Centre for Disease Prevention and Control and the Centers for Disease Control and Prevention, to create a standardized international terminology with which to describe acquired resistance profiles in Staphylococcus aureus, Enterococcus spp.
8,695 citations
••
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) as discussed by the authors was used to estimate the incidence, prevalence, and years lived with disability for diseases and injuries at the global, regional, and national scale over the period of 1990 to 2015.
5,050 citations
••
McGill University1, Ludwig Maximilian University of Munich2, The Royal Marsden NHS Foundation Trust3, Autonomous University of Barcelona4, Geelong Hospital5, University of Marburg6, University of Edinburgh7, Pontifícia Universidade Católica do Rio Grande do Sul8, National Taiwan University9, University of Copenhagen10, Tel Aviv Sourasky Medical Center11, Russian Academy12, University of Düsseldorf13, University of Hamburg14, University of British Columbia15, University of Bern16, Hoffmann-La Roche17, Université libre de Bruxelles18, Harvard University19
TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Abstract: background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy. methods This international, multicenter, randomized trial compared one or two years of trastuzumab given every three weeks with observation in patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy. results Data were available for 1694 women randomly assigned to two years of treatment with trastuzumab, 1694 women assigned to one year of trastuzumab, and 1693 women assigned to observation. We report here the results only of treatment with trastuzumab for one year or observation. At the first planned interim analysis (median follow-up of one year), 347 events (recurrence of breast cancer, contralateral breast cancer, second nonbreast malignant disease, or death) were observed: 127 events in the trastuzumab group and 220 in the observation group. The unadjusted hazard ratio for an event in the trastuzumab group, as compared with the observation group, was 0.54 (95 percent confidence interval, 0.43 to 0.67; P<0.0001 by the log-rank test, crossing the interim analysis boundary), representing an absolute benefit in terms of disease-free survival at two years of 8.4 percentage points. Overall survival in the two groups was not significantly different (29 deaths with trastuzumab vs. 37 with observation). Severe cardiotoxicity developed in 0.5 percent of the women who were treated with trastuzumab. conclusions One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (clinicaltrials.gov number, NCT 00045032.)
4,815 citations
••
TL;DR: Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks.
3,870 citations
••
University of Texas MD Anderson Cancer Center1, American College of Radiology2, University of Texas Health Science Center at Houston3, Tel Aviv Sourasky Medical Center4, Cleveland Clinic5, University of Utah6, Ohio State University7, University of Wisconsin-Madison8, Mayo Clinic9, University of Virginia10, St. Joseph's Hospital and Medical Center11, Thomas Jefferson University12, Emory University13, University of Maryland, Baltimore14
TL;DR: First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma, and progression-free survival was prolonged but did not reach the prespecified improvement target.
Abstract: Background Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with newly diagnosed glioblastoma is not known. Methods In this randomized, double-blind, placebo-controlled trial, we treated adults who had centrally confirmed glioblastoma with radiotherapy (60 Gy) and daily temozolomide. Treatment with bevacizumab or placebo began during week 4 of radiotherapy and was continued for up to 12 cycles of maintenance chemotherapy. At disease progression, the assigned treatment was revealed, and bevacizumab therapy could be initiated or continued. The trial was designed to detect a 25% reduction in the risk of death and a 30% reduction in the risk of progression or death, the two coprimary ...
2,181 citations
Authors
Showing all 6089 results
Name | H-index | Papers | Citations |
---|---|---|---|
Howard L. Weiner | 144 | 1047 | 91424 |
Paul Zimmet | 128 | 740 | 140376 |
Benjamin Geiger | 111 | 397 | 51245 |
David A. Schwartz | 110 | 958 | 53533 |
Joseph E. Schwartz | 108 | 640 | 47880 |
Jeffrey M. Hausdorff | 106 | 401 | 52287 |
Nir Giladi | 98 | 471 | 37237 |
Thomas Braun | 96 | 744 | 38576 |
Prashanthan Sanders | 93 | 676 | 34146 |
Yehuda Carmeli | 88 | 351 | 37154 |
Jonathan M. Kalman | 86 | 441 | 31619 |
David Wallach | 81 | 315 | 30253 |
Amos D. Korczyn | 80 | 582 | 32820 |
Hermona Soreq | 80 | 503 | 25411 |
Itzhak Fried | 78 | 249 | 25324 |